Neuromyelitis Optica Spectrum Disorder Market Size, Share & Trends Analysis and Forecast 2021-2030
All the vital news, analysis, and commentary curated by our industry experts.
The neuromyelitis optica spectrum disorder (NMOSD) market in China was valued at $116.1 million in 2020. Over the 10-year forecast period, the market is projected to grow at a Compound Annual Growth Rate (CAGR) of more than 20%. Major driver for the growth of the market will be the introduction of novel pipeline agents. In order of entry, these products will be Uplizna (inebilizumab), telitacicept, and Ultomiris (ravulizumab). Therefore, the gradual shift towards the use of biologics and mAbs is forecasted to further drive the market growth, because of the emerging clinical evidence of their efficacy in reducing NMOSD attacks coupled with the recent drug pricing reforms that aim to increase reimbursement of innovative drugs.
The greatest unmet need in the NMOSD market is the high cost of innovative drugs including mAbs, in addition to their treatment-related costs. However, this situation is expected to be addressed in the future due to the recent reforms to the country’s National Reimbursement Drug List (NRDL) and revised price cuts with foreign pharma companies. Furthermore, the need for efficacious preventative therapies is expected to be addressed with the launch of a few effective disease-modifying biologics during the forecast period. NMOSD market will exhibit significant growth between 2020 and 2030, driven by the launches of late-stage pipeline agents and the anticipated increased reimbursement of biologics.
Overview of the neuromyelitis optica spectrum disorder market
For more insights on this report, download a free report sample
What are the drugs being used for the neuromyelitis optica spectrum disorder (NMOSD)?
In 2020, the top-selling marketed drug was found to be Soliris, primarily due to its extremely high cost. However, it is anticipated to show a marked decline after 2026, when the patent for Soliris expires and the introduction of its biosimilars such as Samsung Bioepis SB12 (AMT904) start gaining market share. Between 2020 and 2030, all the marketed corticosteroids and off-label immunosuppressants except for mAbs and biosimilars will see an overall decline in sales, due to the shift towards using biologics that are more effective in relapsing NMOSD.
The projected entry of three late-stage pipeline agents into the market over the forecast period is expected to coincide with the increased use of novel mAbs and biosimilars. This presents an opportunity for increased reimbursement and pricing negotiations to further expand the target patient pool. The pipeline drug that will gain the largest market share will be Uplizna in 2030.
Neuromyelitis optica spectrum disorder (NMOSD) by drug and classes, 2020
For more channel insights, download a free report sample
What are the diagnosed prevalent cases of neuromyelitis optica spectrum disorder in China?
The diagnosed prevalent cases of NMOSD in China was 50,598 in 2020 and is forecasted to reach 51,320 cases by 2030, at an annual growth rate of 0.14%. The two clinically and commercially relevant phenotypes considered in this forecast are NMOSD (AQP4+) and NMOSD (AQP4-). In 2020, in China, there were 42,098 cases of AQP4+ and 8,500 cases of AQP4- diagnosed prevalent cases of NMOSD among men and women of all ages.
What is the neuromyelitis optica spectrum disorder (NMOSD) pipeline overview in China?
The NMOSD pipeline in China is varied, with several novel therapeutic classes. Their mechanisms of action (MOAs) range from immunosuppressive strategies and B cell depletion to mAbs seeking label expansion.
Clinical development for NMOSD has steadily grown in recent years; there are currently three pipeline drugs in late-stage development. All these drugs are expected to be launched throughout the forecast period.
There are seven pipeline products in active development for NMOSD in China in Phases I, II, and III. The majority of those are innovative IV-administered biologic drugs. Recent reforms have accelerated the approval process of biologics from material submission to final approval to nearly six months. Therefore, the focus of drug developers in the NMOSD pipeline has been agents that lower the risk of attacks and relapses in patients with AQP4 autoantibodies, which in turn reduces the risk of disabilities.
Market report scope
|Market size of China
(Year – 2020)
|Growth rate of China||CAGR of >20% from 2021 to 2025|
|Base year for estimation||2020|
This report provides a comprehensive analysis of the neuromyelitis optica spectrum disorder market:
- Overview of NMOSD, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized NMOSD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (anti-AQP4+ NMOSD and anti-AQP4- NMOSD) forecast from 2020 to 2030.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the NMOSD therapeutics market. Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for NMOSD therapy. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global NMOSD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Report deliverables include a PowerPoint report and Excel-based forecast model
Forecasts include one country
Forecasts cover three time points: base year, 5-year, and 10-year
The prevalence of NMOSD is increasing in line with population growth in China.
Major unmet needs are expected to be partially addressed by 2030, however, the opportunity to develop a curative drug remains.
The NMOSD pipeline is dominated by innovative biologics that are looking to suppress the risk of relapses and disabilities.
NMOSD market will exhibit significant growth between 2020 and 2030, driven by the launches of late-stage pipeline agents and the anticipated increased reimbursement
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global NMOSD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the NMOSD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Alexion Pharmaceuticals’ (Shanghai)
Jiangsu Hansoh Pharmaceuticals
Yantai Rongchang Pharmaceuticals
Table of Contents
Table of Contents (PowerPoint Deck)
1. Executive Summary
1.1 Executive Summary
2. Disease Overview
2.1 Overview of Neuromyelitis Optica Spectrum Disorder
2.2 Neuromyelitis Optica Spectrum Disorder SWOT Analysis
2.3 Classification of Neuromyelitis Optica Spectrum Disorder
3.1 Diagnosed Prevalent Cases of Neuromyelitis Optica Spectrum Disorder, 2020-2030
3.2 Diagnosed Prevalent Cases of Neuromyelitis Optica Spectrum Disorder by Types, All Ages, N, 2020
3.3 Sources and Methodology for Diagnosed Prevalent Cases of NMOSD and Diagnosed Prevalent Cases of NMOSD by Phenotype
3.4 Sources and Methodology – Diagnosed Prevalent Cases of NMOSD and Diagnosed Prevalent Cases of NMOSD by Phenotype
4. Current Treatment Options
4.1 Treatment Paradigm
4.2 Marketed Products
4.3 Product Profile: Corticosteroids (Methylprednisolone and Prednisone)
4.4 Product Profile: Azathioprine (AZA)
4.5 Product Profile: Mycophenolate mofetil (MMF)
4.6 Product Profile: Roche’s Rituxan/ MabThera (rituximab)
4.7 Product Profile: Alexion Pharmaceuticals’ (Shanghai) Soliris (eculizumab)
4.8 Product Profile: Shanghai Roche’s Enspryng (satralizumab)
5. Unmet Needs and Opportunities
5.1 Unmet Needs in Neuromyelitis Optica Spectrum Disorder
6. R&D Strategies
6.1 Trends in Clinical Trial Design in Neuromyelitis Optica Spectrum Disorder
6.2 Trends in Deal-Making in Neuromyelitis Optica Spectrum Disorder
7. Pipeline Assessment
7.1 Neuromyelitis Optica Spectrum Disorder Pipeline Overview
7.3 Late-Stage Pipeline Agents
7.3 Product Profile: Mitsubishi Tanabe/Viela Bio’s Uplizna (inebilizumab)
7.4 Product Profile: Yantai Rongchang/RemeGen’ Telitacicept
7.5 Product profile: Alexion’s Ultomiris (ravulizumab)
8. Market Outlook
8.1 Neuromyelitis Optica Spectrum Disorder Market Forecast
8.2 Market Drivers and Barriers
9.1 Primary Research: KOL Information
9.3 About the Authors
10. Contact Us
Frequently asked questions
What is the value of the neuromyelitis optica spectrum disorder market in China for the year 2020?
The neuromyelitis optica spectrum disorder market in China was valued at $116.1 million in 2020.
What is the growth rate of the neuromyelitis optica spectrum disorder in China market?
The neuromyelitis optica spectrum disorder market in China is projected to grow at a CAGR of more than 20% during the period 2021-2025.
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.